iData Research, a global consulting and market research firm, has released exclusive research on the U.S. orthopedic biomaterials market. The research addresses key insights including the effects of COVID-19 in 2020 and beyond. While the market is down from previous years, iData’s forecasts show an increase in the patient population age, clinical efficacy results, and popularity surrounding cellular allografts, leading to a strong recovery moving forward.
According to iData’s U.S. Report for Orthopedic Biomaterials, the U.S. market was estimated at just over $3.6 billion in 2019. This market experienced a substantial decline in 2020 following COVID-19 headwinds due to delayed procedures. However, the market has started to recover moving into 2021 and is expected to reach almost $5.3 billion by 2025. This report includes fully segmented procedure volumes of all orthopedic biomaterials by indication, by type, and by injection cycle, as well as unit sales, average selling prices, market drivers and limiters, competitive market share analysis, and more.
iData’s analysis covers the orthopedic bone graft market, orthopedic growth factor market, cellular allograft market, orthopedic cell therapy market, hyaluronic acid viscosupplementation market, and the orthopedic cartilage repair market. Among the six segments included in the overall market, the largest is hyaluronic acid viscosupplementation. Alone, this market has a valuation of over $1.1 billion, constituting one-third of the overall market. Hyaluronic acid viscosupplementation products will be a driver of the market’s projected growth over the forecast period.
“In 2020, the total number of traumatic orthopedic injury rates and scheduled orthopedic procedures reduced significantly”, says Dr. Kamran Zamanian, Senior Partner and CEO of iData Research, “however, as more Americans get vaccinated and restrictions are lifted, the market will return to previous trajectories by 2022.”
Among the many competitors within these markets, Medtronic, DePuy Synthes, and Zimmer Biomet are the leaders followed by Sanofi and Ferring Pharmaceuticals. Stryker, NuVasive, and Wright Medical are trailing the leaders by a substantial margin, pushing for a larger share of the U.S. market. There is a multitude of other competitors analyzed within this report which have one or more products offered in this space.
To accurately estimate market shares, units sold, average selling prices, product segments, and brands as well as procedural volumes, iData Research uses its proprietary market and procedure databases, as well as hospital purchase order data to complement its primary and secondary research initiatives.